<DOC>
	<DOCNO>NCT03062787</DOCNO>
	<brief_summary>It post-license , multicenter , randomize , single blind , control study compare single injection Cingal® ( study arm ) single injection Monovisc® ( control arm ) .</brief_summary>
	<brief_title>Early Effect Cingal® Compared Monovisc® Patients With Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Age &gt; 18 year age Diagnosed osteoarthritis knee Candidate intraarticular injection ( single joint , unilateral ) Monovisc® Cingal® part routine clinical care accordance locally approve label Previous intraarticular injection within last 6 month enrolment Known hypersensitivity corticosteroid , hyaluronic acid component Cingal® Monovisc® Infectious , traumatic neoplasic component knee pathology Surgery knee within last 6 month schedule surgery next two month enrolment Patients impaired cardiorenal function , endocrine , diseases condition use corticosteroid warn . Patients know bleed disorder Patient currently treat oral steroid opioids Patients , investigator ' opinion , unlikely comply protocol Pregnant nursing woman woman suspect might pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>